DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023.
- DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced the appointment of Virginie Boucinha as its Chief Financial Officer, effective November 6, 2023.
- “I am pleased to welcome Virginie to the DBV Executive Committee to lead our global financial organization,” said Daniel Tassé, Chief Executive Officer, DBV Technologies.
- I am looking forward to this mission and to collaborating alongside the broader DBV Executive team.”
Sébastien Robitaille, Chief Financial Officer, DBV Technologies, will be leaving the Company to pursue other opportunities on November 17th. - “It has been a privilege to work alongside colleagues that are dedicated and passionate about making a difference in the lives of others,” said Sébastien Robitaille, Chief Financial Officer, DBV Technologies.